<DOC>
	<DOCNO>NCT00440063</DOCNO>
	<brief_summary>This study determine whether 8 weekly monitoring hemoglobin iron parameter correction phase NeoRecormon therapy patient renal anemia safe effective 4 weekly monitoring . Patients chronic kidney disease receive NeoRecormon dose aim achieve maintain Hb level 110-130g/L . They randomize one two schedule monitor hemoglobin level iron parameter , either 4 weekly 8 weekly . The anticipated time study treatment 3-12 month , target sample size 100-500 inidividuals .</brief_summary>
	<brief_title>A Study NeoRecormon ( Epoetin Beta ) Patients With Renal Anemia .</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>adult patient , 1880 year age ; stage 34 chronic kidney disease ( eGFR 1560mL/min ) ; Hb &lt; 100g/L , TSAT &gt; =20 % , ferritin &gt; =100 mcg/L screening . anticipate go renal replacement therapy ; anticipate live relateddonor kidney transplant , prior recipient kidney transplant ; uncontrolled hypertension ; congestive heart failure ; active bleeding red blood cell transfusion 8 week prior screen ; systematic hematological disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2007</verification_date>
</DOC>